Abstract:Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in awide variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells upon T cell activation. After engagement with its ligands, mainly PD-L1, PD-1 is activated and recruits the phosphatase SHP-2 in proximity to T cell receptor (TCR) and CD28 signaling. This event results in dephosphorylation and attenuation of key molecules in TCR and CD28 pathway, leading to inhibition of T cell proliferation, activation, cytokine production, altered metabolism and cytotoxic T lymphocytes (CTLs) killer functions, and eventual death of activated T cells. Bodies evolve coinhibitory pathways controllingTcell response magnitude and duration to limit tissue damage and maintain self-tolerance. However, tumor cells hijack these inhibitory pathways to escape host immune surveillance by overexpression of PD-L1. This provides the scientific rationale for clinical application of immune checkpoint inhibitors in oncology. The aberrantly high expression of PD-L1 in tumor microenvironment (TME) can be attributable to the "primary" activation of multiple oncogenic signaling and the "secondary" induction by inflammatory factors such as IFN-.. Clinically, antibodies targeting PD-1/PD-L1 reinvigorate the "exhausted" T cells in TME and show remarkable objective response and durable remission with acceptable toxicity profile in large numbers of tumors such as melanoma, lymphoma, and mismatch-repair deficient tumors. Nevertheless, most patients are still refractory to anti-PD-1/PD-L1 therapy. Identifying the predictive biomarkers and design rational PD-1-based combination therapy become the priorities in cancer immunotherapy. PD-L1 expression, cytotoxic T lymphocytes infiltration, and tumor mutation burden (TMB) are generally considered as the most important factors affecting the effectiveness of PD-1/PD-L1 blockade. The revolution in cancer immunotherapy achieved by PD-1/PD-L1 blockade offers the paradigm for scientific translation from bench to bedside. The next decades will without doubt witness the renaissance of immunotherapy.

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

PD-1 and its ligands are important immune checkpoints in cancer

The emerging roles of PD-L1 subcellular localization in tumor immune evasion

PD-1 regulation in immune homeostasis and immunotherapy

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy

Regulatory mechanisms of PD-1/PD-L1 in cancers

Regulation of PD-L1 expression in the tumor microenvironment

PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer

Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade

PD-1/PD-L1 in disease

PD-L1 on Host Cells is Essential for PD-L1 Blockade–mediated Tumor Regression

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape

PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade

PD-1/PD-L1 pathway: current researches in cancer.